Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019693 (HIV)
 170,526 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

ACTG 333 tested the effectiveness of other protease inhibitors in patients who had been on saquinavir for two years. Early data showed that neither indinavir (Crixivan) nor the new version of saquinavir known as the soft gel cap (SGC) had an effect on T4 cell counts or HIV levels. The people in the study only switched their protease inhibitor, not the other anti-HIV drugs that they were taking. As a result, new Federal guidelines specify that all anti-HIV drugs should be changed when protease inhibitors are changed. The U.S. Public Health Service also recommends against using saquinavir as a first protease inhibitor because it is poorly absorbed by the body.
 ...
PMID:Saquinavir update. 1136 16

The Food and Drug Administration (FDA) warns that the antihistamine terfenadine, found in Seldane and Seldane-D, cannot be taken with Crixivan, Norvir, Invirase, Fortovase, and Viracept. Taking terfenadine products with these anti-HIV drugs can lead to a potentially fatal heart condition. The FDA formerly suggested taking the drug off the market and replacing it with Allegra (faxofenadine hydrochloride), a safer drug.
 ...
PMID:Seldane warnings. 1136 51

People who take protease inhibitors are beginning to report strange physical changes, including breast enlargement and accumulations of fat in the upper back and stomach. Although there is no evidence linking these changes to any particular drug, the symptoms are being referred to as Crix belly, from Crixivan, the most popularly prescribed protease inhibitor. Patients claim that they are continuing to lose mass in their face and extremities while gaining weight overall with this condition. Some clinicians say the metabolic changes are showing up in 5 to 10 percent of their patients. The Forum for Collaborative HIV Research, a partnership of public and private AIDS research groups, is studying the condition. One study planned will assess the prevalence and nature of the metabolic symptoms, and another will follow a group on antiretroviral therapy and track their blood chemistry levels.
 ...
PMID:Protease paunch? 1136 56

HIV patients taking protease inhibitors are sometimes reporting a wasting-related syndrome called lipodystrophy, Lipodystrophy is a condition in which the body does not process fats properly. Symptoms include loss of fat from the face and upper body, muscle loss in the arms and legs, pot belly, and abnormal fatty deposits referred to as buffalo humps. Diabetes occasionally occurs, and blood triglycerides are elevated. The syndrome was initially seen in patients on Crixivan, although use of other protease inhibitors can also cause this side effect. The forum for Collaborative AIDS Research is developing a clinical trial to learn more about this symptom. Patients experiencing the symptoms of lipodystrophy should contact the forum for Collaborative AIDS Research.
 ...
PMID:Metabolic problems and PIs. 1136 32

The Treatment Education Project, an initiative of the Staten Island AIDS Task Force, often responds to requests for information on the effects of recreational drugs on people taking anti-HIV medications. There is very little research on the topic because the drugs are illegal and the effects tested with chemically pure street drugs are not likely to mirror those in the population using varied strengths and qualities of the drugs. There have been some controlled studies with methadone, and there is a trial underway to test the use of Marinol and marijuana with Crixivan. The Treatment Education Project also provides counseling, maintains Internet sites in both English and Spanish, and sets up treatment libraries. They also provide workshops for social service agencies and staff.
 ...
PMID:Recreational drugs, methadone and protease inhibitors. 1136 55

Anti-HIV therapy research continues to show promising results and a research update is presented on the following antiviral topics: efavirenz (DMP 266, Sustiva), indinavir (Crixivan), indinavir plus ritonavir (Norvir), hard vs. soft gel saquinavir, nelfinavir (Viracept) cross-resistance, and T-20 (pentafuside). Tables present regimen results, including viral load drop and CD4 cell increases. Difficulties in preventing viral resistance are also discussed. Situations to avoid include using dosing schedules that do not sufficiently suppress the virus, waiting for viral load to return to pre-treatment levels before switching drugs, and not switching drugs to at least two new potent compounds when changing combination therapy. The challenge for patients who have failed previous drug therapies is to develop strategies that allow them to extend the effectiveness of their options long enough for at least two new potent drugs to become available.
 ...
PMID:Update on antivirals. 1136 81

Gilead Sciences has seen beneficial results from two trials of adefovir dipivoxil (Preveon) in the treatment of HIV. An additional trial of adefovir dipivoxil was a success, dramatically reducing hepatitis B viral load by 99.99 percent. GS 411 assigned treatment-naive patients to one of five regimens that included indinavir (Crixivan) and adefovir. The results suggest that adefovir, which is metabolized differently and has different side effects, may be an alternative for some nucleoside analogs. GS 408 added adefovir to the regimens of treatment-experienced patients and showed a marked decrease in viral load for those patients who used adefovir versus a placebo. Adefovir dipivoxil may also be used effectively against other viruses such as CMV, HHV6 and Epstein-Barr. Long-term effectiveness in controlling the HIV virus has yet to be determined.
 ...
PMID:Adefovir dipivoxil (Preveon) new results with hepatitis B, HIV. 1136 89

The number of people joining research studies has dropped since stronger and more effective anti-HIV drugs have been manufactured and approved. However, trials are still enrolling people who are not doing well on their current treatments. Information about trials for people who are failing nelfinavir (Viracept) or indinavir (Crixivan) and the eligibility criteria for many of these studies are provided. Several studies for people who have failed one or more treatments are in the planning stages.
 ...
PMID:Other options: clinical trials. 1136 20

Many of the presentations at the 5th Conference on Retroviruses and Opportunistic Infections were prompted by great successes in treating HIV. There are now more than 300 possible drug combinations, and many promising drugs are under development. Results of tests of several drugs, individually and in combination, are presented. Nucleoside analogs, generally in triple combinations, were well tolerated and led to undetectable viral loads. Crixivan is as effective in twice-daily doses as it is in the FDA-mandated three-times-a-day regimen. People with advanced HIV did better when they started with triple combinations with Crixivan, than those with advanced HIV who started on dual therapy or monotherapy. Viracept treatment resulted in undetectable viral loads in up to 92 percent of the participants in a study group. There are several studies underway to test the safety and effectiveness of combinations that include two protease inhibitors. Two experimental drugs, FTC and hydroxyurea (HU), were noted as having strong potential for HIV treatment.
 ...
PMID:Update from the 5th Conference on Retroviruses and Opportunistic Infections. 1136 83

In [name removed] v. Smith County, Texas U.S. Magistrate Judith K. Guthrie dismissed an HIV-infected inmate's suit against prison officials, where he had received less than optimal drug therapy for his disease. Inmate [name removed] received appropriate doses of AZT and 3TC, but initially did not receive Crixivan; when he did receive it, it was at half the dose he took prior to incarceration. Dismissal was based on rulings by the 5th U.S. Circuit Court that inmates suing prison officials, claiming deliberate indifference, must show more than negligence. The judge further dismissed the inmate's claims under the Americans with Disabilities Act (ADA) and the Rehabilitation Act, saying that those Federal statutes are not applicable to correctional facilities. This ruling predated the U.S. Supreme Court's finding that prisons are subject to the ADA statutes.
 ...
PMID:Giving improper dose of HIV drug is not proof of indifference. 1136 30


<< Previous 1 2 3 4 5 Next >>